drugset / Trial / NCT04906109

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects

NCT04906109

Phase 1 Completed 96 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of DA-2803 in healthy subjects

Timeline

Start
2021-07-12
Primary completion
2021-10-05
Completion
2021-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-2803 Unknown
Subject tenofovir alafenamide Small molecule